Cytomegalovirus (CMV) infection caused by platelet transfusions has been a substantial cause of morbidity and mortality in immunocompromised patients with cancer. Patients who receive allogeneic bone marrow/progenitor cell transplantation are at risk for contracting the virus present in blood products because of cytotoxic preparative regimens, immunosupressive (cyclosporin and corticosteroid) therapy or graft-vs-host disease (GvHD) (14). Up to 60% of this patient population will become infected with CMV, and 50% will have CMV disease if no pre-emptive therapy is given. The risk of CMV infection ranges between 28 and 57% for patients receiving a bone marrow transplant and who are seronegative and receive standard blood products (15). Even with CMV-negative blood products, CMV seroconversion has been reported in 1-4% of CMV-negative donor-recipient transplant patients (16). A recent analysis of our own program identified CMV viremia in only 2.5% (1 of 39) of CMV-negative donor-recipient pairs undergoing allogeneic PBPC transplantation (17). Our analysis included 59 patients undergoing allo-geneic PBPC transplantation in an investigational study of prophylactic granulocyte infusions from stem cell donors. Notably, results showed that CMV-positive granulocytes did not alter the risk of viremia compared with CMV-negative granulocytes (34.5% vs 26.6% incidence of CMV viremia, respectively [95% CI 0.47-4.41]).
CMV infection and CMV disease are much less common than other virally transmitted diseases in patients undergoing conventional chemotherapy or autologous bone marrow/progenitor cell transplantation (18) and are not a significant clinical problem except with CD34+-selected or T-cell depleted progenitor cell transplantations (19).
A randomized, controlled clinical trial (15) in patients receiving allogeneic bone marrow transplants compared CMV-seronegative blood products with unscreened blood products that were subjected to bedside leukofiltration. Four (1.3%) of 252 patients in the CMV-seronegative cohort developed CMV infection, with no CMV disease or fatalities; 6 (2.4%) of 250 patients who had bedside leukofiltration developed CMV disease, and 5 of these patients died. Patients who had leukofiltration had an increased probability of developing CMV disease by d 100 (2.4% vs 0%, p = 0.03). Even when investigators eliminated CMV infections occurring within 21 d of transplantation, two patients in the leukofiltration cohort and none in the seronegative cohort died of CMV disease (20). The investigators' conclusions that leukoreduced blood products are CMV-safe remain controversial (21). In a consensus conference held by the Canadian Blood Service (20), 7 of 10 panelists concluded that patients considered at risk for CMV disease should receive CMV-negative products, even when blood components are leukoreduced.
Was this article helpful?
Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.